CLDX

Celldex Therapeutics, Inc. - Q1 2011 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2011. Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing immunotherapy technologies. Key programs include rindopepimut (CDX-110) for glioblastoma multiforme and CDX-011 (glembatumumab vedotin) for breast cancer. The company also generates revenue from royalties on the Rotarix vaccine, commercialized by partner GlaxoSmithKline.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 32% to $2.5 million. This was driven by a $1.3 million drop in product development and licensing revenue due to the termination of the Pfizer agreement in late 2010 (which had generated significant deferred revenue recognition in Q1 2010) and a $0.2 million drop in grant revenue.
• Increased Net Loss: Net loss widened by 53% to $10.1 million. The increase was primarily due to a $3.1 million decrease in investment and other income (specifically the absence of a $3.0 million one-time payment from the TopoTarget agreement received in Q1 2010) and lower licensing revenue.
• Debt Restructuring: The company increased its Term Loan from $10 million to $15 million in March 2011. Concurrently, it paid off $12.5 million in convertible subordinated debt (CuraGen Debt) in February 2011.
• Expense Management: Amortization of acquired intangible assets decreased by 68% ($1.0 million) due to the completion of amortization for the TopoTarget Agreement. General and Administrative expenses decreased 16% largely due to lower stock-based compensation.

Outlook, Risks, and Management Commentary

• Liquidity Position: Management believes current cash, cash equivalents, and marketable securities ($44.3 million), plus $2.1 million raised in April 2011 via the Cantor Agreement, are sufficient to fund operations for at least the next 12 months.
• Capital Needs: The company plans to raise additional capital for long-term needs through licensing, business combinations, debt, or equity offerings. There is no assurance that financing will be available on acceptable terms.
• Development Milestones: The company plans to initiate a pivotal Phase 3 randomized study for rindopepimut in the second half of 2011. Enrollment for the Phase 2b study of CDX-011 in breast cancer is expected to complete in 2011.
• Risks: Key risks include the inability to raise capital, failure of clinical trials, and the uncertainty of regulatory approvals. The company faces potential dilution from equity financing and restrictive covenants from debt financing.
• Unusual Items: The Q1 2010 results included a $3.0 million one-time gain from the TopoTarget agreement, making year-over-year comparisons of income and cash flow less indicative of recurring performance.

Investor Verification Checklist

• Verify the timeline and funding requirements for the planned Phase 3 trial of rindopepimut.
• Confirm the status of the Cantor Agreement equity sales and the total capital raised post-filing.
• Review the terms of the $15 million Term Loan, specifically the interest rate (LIBOR + 6.25% or 9.50% minimum) and repayment schedule starting October 2011.
• Monitor the royalty dispute with GlaxoSmithKline regarding Rotarix patent coverage in Australia and Europe, which impacts royalty rates.
• Assess the burn rate relative to the $44.3 million liquidity position to determine the runway for operations without additional financing.